Page 22 - Nsclc News Today

Ticiana Leal, MD, gives a comprehensive overview of treatment options for patients with EGFR-mutated NSCLC who progress on osimertinib therapy.

A panel discusses the role of neoadjuvant therapy in the current treatment approach for early stages of NSCLC.

Experts deliberate on the optimal timing of chemoimmunotherapy and if it should be before or after surgery.

The approval allows for continuous immunotherapy treatment around surgery for resectable non-small cell lung cancer.

Genentech, Inc., affiliated to Swiss drug major Roche Holding AG (RHHBY), announced Wednesday results from the primary analysis of the Phase III ALINA study of Alecensa (alectinib) in people with anaplastic lymphoma kinase or ALK-positive non-small cell lung cancer or NSCLC.

David S. Hong, MD, discusses preliminary efficacy data from a phase 1 trial f the KRAS G12C inhibitor RMC-6291 in advanced KRAS G12C–mutant solid tumors.

School nurses play an overworked and understaffed role; Merck's immunotherapy Keytruda (pembroilzumab) has been granted approval for pre- and postsurgical treatment in lung cancer; the FDA is helping to curb tobacco-related health disparities.

The anti–PD-1 agent pembrolizumab was granted a new indication to treat patients with resectable non–small cell lung cancer (NSCLC) as a neoadjuvant treatment with chemotherapy and continued as adjuvant treatment after surgery.

The FDA has approved pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment for patients with resectable non–small cell lung cancer.

Omar Abughanimeh, MD, discusses the evolution of targeted therapies for patients with EGFR-positive non-small cell lung cancer.